Naftifine adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Naftifine}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NAFTIN (NAFTIFINE HYDROCHLORIDE) CREAM [MERZ PHARM...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Adverse Reactions== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NAFTIN (NAFTIFINE HYDROCHLORIDE) CREAM [MERZ PHARMACEUTICALS, LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4b6c5d8-615c-47d6-8ad9-523c7ab146af | publisher = | date = | accessdate = }}</ref> | During clinical trials with Naftin® Cream, 1%, the incidence of adverse reactions was as follows: burning/stinging (6%), dryness (3%), erythema (2%), itching (2%), local irritation (2%). During clinical trials with Naftin® Gel, 1%. the incidence of adverse reactions was as follows: burning Istinging (5.0%), [[itching]] (1.0%), [[erythema]] (0.5%), [[rash]] (0.5%), skin tenderness (0.5%).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NAFTIN (NAFTIFINE HYDROCHLORIDE) CREAM [MERZ PHARMACEUTICALS, LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4b6c5d8-615c-47d6-8ad9-523c7ab146af | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Latest revision as of 03:39, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Adverse Reactions
During clinical trials with Naftin® Cream, 1%, the incidence of adverse reactions was as follows: burning/stinging (6%), dryness (3%), erythema (2%), itching (2%), local irritation (2%). During clinical trials with Naftin® Gel, 1%. the incidence of adverse reactions was as follows: burning Istinging (5.0%), itching (1.0%), erythema (0.5%), rash (0.5%), skin tenderness (0.5%).[1]
References
Adapted from the FDA Package Insert.